Health
Senhwa Biosciences Secures Strategic Backing from Global Investor GEM with Up to NT$500 Million to Accelerate AI-Driven Drug Development
TAIPEI and SAN DIEGO, April 14, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company announced today the signing of a Memorandum of Understanding (MOU) with GEM YIELD BAHAMAS LIMITED, an affiliate of the global investment firm Global Emerging Mark...
2026-04-14 15:11
2749
Boston Aesthetics Appoints Brandon Nye as Chief Executive Officer to Drive Next Phase of Commercial Growth
IRVINE, Calif., April 13, 2026 /PRNewswire/ – Boston Aesthetics today announced the appointment of Brandon Nye as Chief Executive Officer, effective immediately. Nye will lead the company's strategic growth initiatives, commercial expansion, and operating execution as Boston Aesthetics enters its...
2026-04-13 23:00
2897
Caliway's Fat Reduction Drug CBL-514 Phase 2 Clinical Results Accepted by ASJ. CBL-0204's Demonstrated Efficacy and Safety Gain Further Academic Recognition
* Clinical results from Caliway's CBL-0204 Phase 2b study of its fat reduction drug candidate CBL-514 for localized fat reduction have been accepted by theAesthetic Surgery Journal (ASJ), a leading academic journal in aesthetic medicine and plastic surgery. * Following the publication of CBL-...
2026-04-13 16:34
3238
Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain
BEIJING, April 13, 2026 /PRNewswire/ -- On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants AbbVie the e...
2026-04-13 14:24
3228
Helping Pets Breathe Easier with VARON Oxygen Therapy Bundles
NEW YORK, April 11, 2026 /PRNewswire/ -- When every breath becomes a struggle
for a pet, timely pet oxygen concentrator can make a meaningful difference.
Until recently, this level of care was largely limited to veterinary clinics.
VARON
2026-04-11 17:06
2723
SINGAPORE STRENGTHENS SARCOMA CARE THROUGH COORDINATED, MULTIDISCIPLINARY APPROACH
NCIS leads multi-institutional effort to develop expert multidisciplinary guidance to improve sarcoma diagnosis, referrals and outcomes SINGAPORE, April 11, 2026 /PRNewswire/ -- Singapore is strengthening its approach to sarcoma care, a rare group of bone and soft tissue cancers that disproporti...
2026-04-11 16:20
3368
Vivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development
* Advancing next-generation RNA therapeutics beyond the liver through breakthrough delivery technologies SUZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ -- Vivatides Therapeutics, a global biotechnology company focused on developing extrahepatic RNA-targeting therapeutics, announced the s...
2026-04-10 20:00
4533
Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
SHANGHAI, April 9, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies,today announced the cumulative closing of a pre-IPO financing round in excess of $110 million. The round was co-led...
2026-04-10 08:00
3975
NEXTBIOMEDICAL Secures Exclusive Distribution Agreement for Nexsphere-F™ in Japan
SEOUL, South Korea, April 9, 2026 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that it has entered into an exclusive distribution agreement in Japan with Asahi Intecc Co., Ltd., a global medical device compan...
2026-04-09 21:00
3781
DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
SHANGHAI, April 9, 2026 /PRNewswire/ -- DualityBio ("DualityBio" or the "Company", Stock Code: 9606.HK) today announced that the Biologics License Application (BLA) for the investigational antibody-drug conjugate ("ADC") trastuzumab pamirtecan ("T-Pam", also known as DB-1303 or BNT323), has been ...
2026-04-09 19:55
4010
111, Inc. Announces Fourth Quarter and Fiscal Year 2025 Financial Results
* Continuing Transition to an Asset-Light Business Model to Improve Overall Efficiency * Delivered Non-GAAP Operating Profitability in Both Q4'25 and FY'25 * Generated Positive Operating Cash Flow for Both Q4'25 and FY'25 * Continued Gross Profit Margin Expansion for B2B Business in Both Q4...
2026-04-09 15:00
6538
Big Tree Cloud Holdings Limited Announces Transfer of Listing to Nasdaq Capital Market
SHENZHEN, China, April 8, 2026 /PRNewswire/ -- Big Tree Cloud Holdings Limited (the "Company") (NASDAQ: DSY) today announced that on April 7, 2026, it received approval from The Nasdaq Stock Market LLC ("Nasdaq") to transfer the listing of its Class A Ordinary Shares from the Nasdaq Global Market...
2026-04-09 04:15
5759
Portrai to Present 11 Posters on AI-Driven Spatial Transcriptomics at AACR 2026
The South Korean spatial biology company unveils new AI agents, foundation models, and spatial biomarkers for oncology drug discovery. SEOUL, South Korea, April 8, 2026 /PRNewswire/ -- Portrai, Inc. today announced it will present 11 posters highlighting its artificial intelligence and spatial t...
2026-04-08 17:50
3103
ATLATL Announces Agreement with Daiichi Sankyo to Deepen APAC Biotech Innovation
SHANGHAI, April 7, 2026 /PRNewswire/ -- ATLATL Innovation Center (hereinafter referred to as "ATLATL"), a global innovation platform for life science research and development, announced an agreement with Daiichi Sankyo to leverage ATLATL's multi-regional innovative R&D network and expertise in the...
2026-04-08 14:08
3070
Totaria Celebrates World Health Day 2026: Harnessing Science to Advance Global Wellness
Science-backed high-absorption health supplements for everyday nutritional support AURORA, Colo, April 7, 2026 /PRNewswire/ -- Totaria, a premium American nutritional supplement brand, is introducing its full lineup of high-absorption health supplements on the occasion of World Health Day 2026 u...
2026-04-07 22:02
3267
Singlomics Announces First Patient Dosed in Phase I Clinical Trial of DXP-106 (IL-1RAP mAb) in China
BEIJING, April 7, 2026 /PRNewswire/ -- Singlomics Biopharmaceuticals, an innovative clinical-stage biopharmaceutical company focused on the discovery and development of antibody therapeutics for oncology, inflammation, and autoimmune diseases, today announced that the first patient has been dosed...
2026-04-07 21:00
3172
Jin Medical International Ltd. Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
CHANGZHOU, China, April 7, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated entities, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment, today announced that it has receive...
2026-04-07 19:00
2872
Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
HONG KONG, April 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a median follow-up of 21.45 months from a prospective, open-label, single-arm, multicenter Phase Ib/II ...
2026-04-07 11:28
2643
Alar Breaks Key Barriers in Ketamine Therapy with Positive Phase 1 Results for Long-Acting Injectable ALA-3000 for Treatment-Resistant Depression
* By reducing dissociation and sedation risk, ALA-3000 may eliminate the ≥2-hour post-dose monitoring requirement, reducing clinic operating costs, improving patient throughput, and supporting a more cost-effective and reimbursement-aligned treatment model. TAICHUNG, April 6, 2026 /PRNewswire/ ...
2026-04-06 20:00
GC Biopharma Enhances IVIG Safety Profile with Advanced Prothrombotic Impurity Detection Technology
* Proprietary analytical method for precise Factor XI (FXI) measurement published in the Journal of Microbiology and Biotechnology * Novel IgG Blocker eliminates heterophilic antibody interference, ensuring clinical-grade purity and mitigating thromboembolic risks YONGIN, South Korea, April 6...
2026-04-06 14:28
Week's Top Stories
Most Reposted
Agoda Establishes Strategic Partnership with Taipei City Government, Promoting International Tourism Development
[Picked up by 312 media titles]
2026-04-16 17:15
Hai Robotics and Maersk Redefine Fashion Fulfilment with High-Density Robotics at 10-Metre Scale in Singapore
[Picked up by 298 media titles]
2026-04-14 10:00
Blaize and Winmate Announce Strategic Collaboration to Advance Sovereign Edge AI Capabilities for Defense and Critical Infrastructure
[Picked up by 296 media titles]
2026-04-16 18:00
One Bangkok Hosted "Sunsational Songkran Festival 2026"
[Picked up by 289 media titles]
2026-04-16 15:34
Silicon Box Announces It Joins Imec Automotive Chiplet Program to Strengthen Chip Supply Chains for Next-Generation Vehicles
[Picked up by 288 media titles]
2026-04-15 21:02
Most Read
Blaize Announces Expected First Quarter 2026 Revenue and Newly Awarded Contract with NeoTensr Anticipated to Generate $50.0 Million in Revenue
2026-04-14 21:43
6467
NYSE Content Update: U.S.-Based Diversified Energy to Ring Bell for 25 Years Since its Founding
2026-04-13 21:06
5820
Makerfire Adopts Breakthrough USX51 Industrial-Grade AI Flight Controller: Empowering Enterprises to Cut Costs and Boost Efficiency in Low-Altitude Operations
2026-04-11 01:00
5594
OCI Global Publishes 2025 Annual Report and Audited Financial Statements
2026-04-11 00:49
5082